← Back to headlines
Gilead Sciences Acquires Ouro Medicines, Collaborates with Galapagos
Gilead Sciences has finalized its acquisition of autoimmune biotech company Ouro Medicines for up to $2 billion and will collaborate with Galapagos on the purchased assets.
23 Mar, 16:33 — 23 Mar, 23:35
The Story
Analyzing sources…
Source Diversity
Source Diversity
High (51/100)4 sources30/33
Spectrum spread— 2/5 buckets covered8/33
Far L
Left
Center2
Center (2)
ReutersFT
Right2
Right (2)
wsjseeking-alpha
Far R
Geographic diversity— 3 regions13/34
US2Intl1UK1
Sources
Showing 3 of 4 sources
ReutersVery High17h ago
Gilead nears up to $2 billion buyout of biotech Ouro Medicines, FT reports - Reuters
Gilead nears up to $2 billion buyout of biotech Ouro Medicines, FT reports Reuters
Read full article →wsjHigh11h ago
Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets - WSJ
Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets WSJ
Read full article →FTVery High18h ago
Gilead nears up to $2bn deal for autoimmune biotech Ouro Medicines
California-based drugmaker takes advantage of surging share price to strike takeovers after a quiet couple of years
Read full article →Coverage Timeline
First report: FT · 23 Mar, 16:33|Full coverage: 4 · 7h|Window: 7h
Left-leaningCenterRight-leaning
Related Stories
PGH Head Nurse Cleared of Fault in P60M Equipment Loss from 2021 Fire
just now
DDB Chief Calls for Stronger Support for Drug Users in the Philippines
just now
Bornavirus, Previously Thought to Affect Only Animals, Can Infect and Kill Humans
12m ago
Air India Introduces New Health Mandate, Including Potential Pay Loss for 'Obese' Staff
12m ago